N/A N=1,930 QuickFlex Micro Left Ventricular Lead Post Approval Study
Heart Failure
Primary: Percent of Participants Alive and Without a Left Ventricular Lead-related Complication — 1902 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=39 Ovarian Morphology and Theca Cell Androgen Production in Women With Polycystic Ovary Syndrome (PCOS)
Polycystic Ovary Syndrome
Primary: Percent Change of 17-OHP Levels From Baseline — 67; 140 percent change
N/A N=14 Contact Lens Insertion and Removal in a Senior Subject Demographic
Visual Acuity
Primary: Overall Success Rate of Insertion and Removal of a Contact Lens — 85.7 Percentage of eyes
N/A N=26 Effects of Octacosanol During Taekwondo Training
Oxidative Stress · Dyslipidemias
Primary: Triglycerides — 34.9; 110 mg/dL
N/A N=146 Ultrasound for Neuraxial Anesthesia
Lumbar Ultrasound
Primary: Number of Participants With Successful Techniques — 74; 63 Participants — p=0.748
Phase 4 N=117 Open-Label Study, Evaluating Patient Satisfaction and Symptom Improvement When Treating Male Hypogonadism With Natesto™
Hypogonadism
Primary: Patient Satisfaction - Change From Baseline — 9.6; 21.5; 18.9; 21.9 Units on a scale
N/A N=400 Increasing Colorectal Cancer (CRC) Screening Among Hispanic Primary Care Patients
Colorectal Cancer
Primary: Overall Screening Adherence — 88; 153; 115; 44 Participants — p=<0.001
Phase 3 N=679 Dose-Ranging Study of Mometasone Furoate (MK-0887/SCH 032088) Nasal Spray in the Treatment of Children (Ages 6-11) With Seasonal Allergic Rhinitis (C95-161)
Rhinitis, Allergic, Seasonal
Primary: Change From Baseline in the Total Nasal Symptom Score (TNSS) at Day 8 as Assessed by Investigator — 7.8; 8.1; 7.9; 8.0 Scores on a scale — p=0.95
N/A N=94 Acupuncture for Fatigue in Parkinson's Disease
Parkinsons Disease
Primary: Change in the Modified Fatigue Impact Scale Total (MFIS) Between Treatment Groups — -13.2; -16.0 units on a scale
N/A N=85 Text Messaging and Cognitive Behavioral Therapy for Depression
Depression
Primary: PHQ-9 Depression Symptoms — 6; 12.67 units on a scale
N/A N=1,529 Advance Cardiac Resynchronization Therapy (CRT) Registry
Heart Failure
Primary: Number of CRT Non-responders Using 1) Clinical Composite Score (CCS) and 2) Site-specific Criteria for Determining CRT Response — 1061; 900 Participants
N/A N=31 Evaluation of a Modified Paleolithic Dietary Intervention in the Treatment of Relapsing-Remitting Multiple Sclerosis
Multiple Sclerosis, Relapsing-remitting
Primary: Change in Fatigue Severity Scale (FSS)-9 Score — 4.20; 3.99; 2.82; 4.25 units on a scale
N/A N=162 Growth Mindset Psychoeducation for Modifiable Risk Factors for CMD
Depression, Anxiety
Primary: Patient Health Questionnaire (PHQ-9; Kroenke, Spitzer & Williams, 2001) — 5.50; 4.57; 6.70; 13.14 units on a scale
Phase 1 N=51 A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma
Soft Tissue Sarcoma
Primary: Percent Change From Baseline in Enumeration of Circulating Tumor Cells (CTCs) in Whole Blood — 846.93; 820.11 percent change
Phase 1 N=24 A Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Needle Safety Device (PFS+NSD) in Healthy Participants
Healthy Volunteers
Primary: AUClast: Area Under the Serum Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Vedolizumab SC — 493.5; 485.8 microgram*day per…